Diabetic Eye Disease Pipeline Therapies Part 3: Brolucizumab & PDS
| Overview / Abstract: |
This discussion with Program Chair Christina Y. Weng, MD, MBA, and Sophie J. Bakri, MD, includes a case study that highlights challenges with managing diabetic eye disease during the COVID era and how longer duration therapies could be beneficial. Drs. Weng and Bakri also converse about the latest data on pipeline therapies for diabetic macular edema, including brolucizumab & PDS. |
|
Expiration |
Dec 30, 2022 |
|
Discipline(s) |
Optometry / Ophthalmology CE |
|
Format |
Online, Webinar / Webcast / Video |
|
Credits / Hours |
0.5 |
|
Accreditation |
ACCME |
|
Keywords / Search Terms |
Evolve Medical Education LLC Free CE CME |
|